加载页面时好像出了点问题.
我们的团队已经注意到了，但如果问题仍然存在，请使用电子邮件支持小工具联系我们。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -15.8x - -17.5x | -16.6x |
| Selected Fwd P/E Multiple | 26.7x - 29.5x | 28.1x |
| Fair Value | 16.81$ - 18.58$ | 17.70$ |
| Upside | -40.1% - -33.8% | -37.0% |
| Benchmarks | - | Full Ticker |
| Ocular Therapeutix, Inc. | - | NasdaqGM:OCUL |
| Omeros Corporation | - | NasdaqGM:OMER |
| Bausch Health Companies Inc. | - | NYSE:BHC |
| CNBX Pharmaceuticals Inc. | - | OTCPK:CNBX |
| Elanco Animal Health Incorporated | - | NYSE:ELAN |
| Harrow, Inc. | - | NasdaqGM:HROW |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| OCUL | OMER | BHC | CNBX | ELAN | HROW | |||
| NasdaqGM:OCUL | NasdaqGM:OMER | NYSE:BHC | OTCPK:CNBX | NYSE:ELAN | NasdaqGM:HROW | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 37.8% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -139.7% | -2.0% | 92.2% | 84.4% | 127.5% | -135.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -382.1% | -106.9% | -8.6% | -39822.4% | -10.2% | -17.2% | ||
| Prior Fiscal Year | -138.1% | NA | -6.8% | -904.6% | -27.9% | -15.9% | ||
| Latest Fiscal Year | -303.7% | NA | -0.5% | -534.5% | 7.6% | -18.7% | ||
| Latest Twelve Months | -303.7% | NA | -0.5% | -1356.0% | 7.6% | -19.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -5.1x | -4.9x | 7.7x | -3.9x | 10.5x | 393.3x | ||
| Price / LTM Sales | 18.6x | NA | 0.3x | 5.8x | 1.2x | 5.9x | ||
| LTM P/E Ratio | -6.1x | -2.9x | -56.9x | -0.4x | 15.4x | -29.8x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -56.9x | -2.9x | 15.4x | |||||
| Historical LTM P/E Ratio | -95.5x | -23.5x | 12.5x | |||||
| Selected P/E Multiple | -15.8x | -16.6x | -17.5x | |||||
| (x) LTM Net Income | (33) | (33) | (33) | |||||
| (=) Equity Value | 528 | 555 | 583 | |||||
| (/) Shares Outstanding | 35.6 | 35.6 | 35.6 | |||||
| Implied Value Range | 14.81 | 15.59 | 16.37 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 14.81 | 15.59 | 16.37 | 28.09 | ||||
| Upside / (Downside) | -47.3% | -44.5% | -41.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | OCUL | OMER | BHC | CNBX | ELAN | HROW | |
| Value of Common Equity | 1,183 | 527 | 2,623 | 0 | 5,233 | 1,000 | |
| (/) Shares Outstanding | 159.0 | 57.9 | 367.9 | 31.1 | 494.6 | 35.6 | |
| Implied Stock Price | 7.44 | 9.10 | 7.13 | 0.01 | 10.58 | 28.09 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 7.44 | 9.10 | 7.13 | 0.01 | 10.58 | 28.09 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |